Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies

Steven J. Skates, Michael A. Gillette, Joshua LaBaer, Steven A. Carr, Leigh Anderson, Daniel C. Liebler, David Ransohoff, Nader Rifai, Marina Kondratovich, Živana Težak, Elizabeth Mansfield, Ann L. Oberg, Ian Wright, Grady Barnes, Mitchell Gail, Mehdi Mesri, Christopher R. Kinsinger, Henry Rodriguez, Emily S. Boja

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Protein biomarkers are needed to deepen our understanding of cancer biology and to improve our ability to diagnose, monitor, and treat cancers. Important analytical and clinical hurdles must be overcome to allow the most promising protein biomarker candidates to advance into clinical validation studies. Although contemporary proteomics technologies support the measurement of large numbers of proteins in individual clinical specimens, sample throughput remains comparatively low. This problem is amplified in typical clinical proteomics research studies, which routinely suffer from a lack of proper experimental design, resulting in analysis of too few biospecimens to achieve adequate statistical power at each stage of a biomarker pipeline. To address this critical shortcoming, a joint workshop was held by the National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), and American Association for Clinical Chemistry (AACC) with participation from the U.S. Food and Drug Administration (FDA). An important output from the workshop was a statistical framework for the design of biomarker discovery and verification studies. Herein, we describe the use of quantitative clinical judgments to set statistical criteria for clinical relevance and the development of an approach to calculate biospecimen sample size for proteomic studies in discovery and verification stages prior to clinical validation stage. This represents a first step toward building a consensus on quantitative criteria for statistical design of proteomics biomarker discovery and verification research.

Original languageEnglish (US)
Pages (from-to)5383-5394
Number of pages12
JournalJournal of Proteome Research
Volume12
Issue number12
DOIs
StatePublished - Dec 6 2013

Fingerprint

Biomarkers
Proteomics
National Heart, Lung, and Blood Institute (U.S.)
Education
Proteins
Aptitude
National Cancer Institute (U.S.)
Validation Studies
United States Food and Drug Administration
Research
Sample Size
Design of experiments
Neoplasms
Consensus
Blood
Research Design
Pipelines
Throughput
Technology

Keywords

  • biomarker
  • power calculation
  • proteomics
  • statistical experiment design
  • unbiasedness

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)
  • Medicine(all)

Cite this

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. / Skates, Steven J.; Gillette, Michael A.; LaBaer, Joshua; Carr, Steven A.; Anderson, Leigh; Liebler, Daniel C.; Ransohoff, David; Rifai, Nader; Kondratovich, Marina; Težak, Živana; Mansfield, Elizabeth; Oberg, Ann L.; Wright, Ian; Barnes, Grady; Gail, Mitchell; Mesri, Mehdi; Kinsinger, Christopher R.; Rodriguez, Henry; Boja, Emily S.

In: Journal of Proteome Research, Vol. 12, No. 12, 06.12.2013, p. 5383-5394.

Research output: Contribution to journalArticle

Skates, SJ, Gillette, MA, LaBaer, J, Carr, SA, Anderson, L, Liebler, DC, Ransohoff, D, Rifai, N, Kondratovich, M, Težak, Ž, Mansfield, E, Oberg, AL, Wright, I, Barnes, G, Gail, M, Mesri, M, Kinsinger, CR, Rodriguez, H & Boja, ES 2013, 'Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies', Journal of Proteome Research, vol. 12, no. 12, pp. 5383-5394. https://doi.org/10.1021/pr400132j
Skates, Steven J. ; Gillette, Michael A. ; LaBaer, Joshua ; Carr, Steven A. ; Anderson, Leigh ; Liebler, Daniel C. ; Ransohoff, David ; Rifai, Nader ; Kondratovich, Marina ; Težak, Živana ; Mansfield, Elizabeth ; Oberg, Ann L. ; Wright, Ian ; Barnes, Grady ; Gail, Mitchell ; Mesri, Mehdi ; Kinsinger, Christopher R. ; Rodriguez, Henry ; Boja, Emily S. / Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. In: Journal of Proteome Research. 2013 ; Vol. 12, No. 12. pp. 5383-5394.
@article{8c757e0aef9643dcb3af291a9d47d425,
title = "Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies",
abstract = "Protein biomarkers are needed to deepen our understanding of cancer biology and to improve our ability to diagnose, monitor, and treat cancers. Important analytical and clinical hurdles must be overcome to allow the most promising protein biomarker candidates to advance into clinical validation studies. Although contemporary proteomics technologies support the measurement of large numbers of proteins in individual clinical specimens, sample throughput remains comparatively low. This problem is amplified in typical clinical proteomics research studies, which routinely suffer from a lack of proper experimental design, resulting in analysis of too few biospecimens to achieve adequate statistical power at each stage of a biomarker pipeline. To address this critical shortcoming, a joint workshop was held by the National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), and American Association for Clinical Chemistry (AACC) with participation from the U.S. Food and Drug Administration (FDA). An important output from the workshop was a statistical framework for the design of biomarker discovery and verification studies. Herein, we describe the use of quantitative clinical judgments to set statistical criteria for clinical relevance and the development of an approach to calculate biospecimen sample size for proteomic studies in discovery and verification stages prior to clinical validation stage. This represents a first step toward building a consensus on quantitative criteria for statistical design of proteomics biomarker discovery and verification research.",
keywords = "biomarker, power calculation, proteomics, statistical experiment design, unbiasedness",
author = "Skates, {Steven J.} and Gillette, {Michael A.} and Joshua LaBaer and Carr, {Steven A.} and Leigh Anderson and Liebler, {Daniel C.} and David Ransohoff and Nader Rifai and Marina Kondratovich and Živana Težak and Elizabeth Mansfield and Oberg, {Ann L.} and Ian Wright and Grady Barnes and Mitchell Gail and Mehdi Mesri and Kinsinger, {Christopher R.} and Henry Rodriguez and Boja, {Emily S.}",
year = "2013",
month = "12",
day = "6",
doi = "10.1021/pr400132j",
language = "English (US)",
volume = "12",
pages = "5383--5394",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies

AU - Skates, Steven J.

AU - Gillette, Michael A.

AU - LaBaer, Joshua

AU - Carr, Steven A.

AU - Anderson, Leigh

AU - Liebler, Daniel C.

AU - Ransohoff, David

AU - Rifai, Nader

AU - Kondratovich, Marina

AU - Težak, Živana

AU - Mansfield, Elizabeth

AU - Oberg, Ann L.

AU - Wright, Ian

AU - Barnes, Grady

AU - Gail, Mitchell

AU - Mesri, Mehdi

AU - Kinsinger, Christopher R.

AU - Rodriguez, Henry

AU - Boja, Emily S.

PY - 2013/12/6

Y1 - 2013/12/6

N2 - Protein biomarkers are needed to deepen our understanding of cancer biology and to improve our ability to diagnose, monitor, and treat cancers. Important analytical and clinical hurdles must be overcome to allow the most promising protein biomarker candidates to advance into clinical validation studies. Although contemporary proteomics technologies support the measurement of large numbers of proteins in individual clinical specimens, sample throughput remains comparatively low. This problem is amplified in typical clinical proteomics research studies, which routinely suffer from a lack of proper experimental design, resulting in analysis of too few biospecimens to achieve adequate statistical power at each stage of a biomarker pipeline. To address this critical shortcoming, a joint workshop was held by the National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), and American Association for Clinical Chemistry (AACC) with participation from the U.S. Food and Drug Administration (FDA). An important output from the workshop was a statistical framework for the design of biomarker discovery and verification studies. Herein, we describe the use of quantitative clinical judgments to set statistical criteria for clinical relevance and the development of an approach to calculate biospecimen sample size for proteomic studies in discovery and verification stages prior to clinical validation stage. This represents a first step toward building a consensus on quantitative criteria for statistical design of proteomics biomarker discovery and verification research.

AB - Protein biomarkers are needed to deepen our understanding of cancer biology and to improve our ability to diagnose, monitor, and treat cancers. Important analytical and clinical hurdles must be overcome to allow the most promising protein biomarker candidates to advance into clinical validation studies. Although contemporary proteomics technologies support the measurement of large numbers of proteins in individual clinical specimens, sample throughput remains comparatively low. This problem is amplified in typical clinical proteomics research studies, which routinely suffer from a lack of proper experimental design, resulting in analysis of too few biospecimens to achieve adequate statistical power at each stage of a biomarker pipeline. To address this critical shortcoming, a joint workshop was held by the National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), and American Association for Clinical Chemistry (AACC) with participation from the U.S. Food and Drug Administration (FDA). An important output from the workshop was a statistical framework for the design of biomarker discovery and verification studies. Herein, we describe the use of quantitative clinical judgments to set statistical criteria for clinical relevance and the development of an approach to calculate biospecimen sample size for proteomic studies in discovery and verification stages prior to clinical validation stage. This represents a first step toward building a consensus on quantitative criteria for statistical design of proteomics biomarker discovery and verification research.

KW - biomarker

KW - power calculation

KW - proteomics

KW - statistical experiment design

KW - unbiasedness

UR - http://www.scopus.com/inward/record.url?scp=84890023096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890023096&partnerID=8YFLogxK

U2 - 10.1021/pr400132j

DO - 10.1021/pr400132j

M3 - Article

C2 - 24063748

AN - SCOPUS:84890023096

VL - 12

SP - 5383

EP - 5394

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 12

ER -